viernes, 31 de mayo de 2019

Are spit tubes a bad business?

The Readout
Damian Garde

Are spit tubes a bad business?

Who's guilty of "clickbait"? And why are academics emulating Pusha T?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss Novartis's decision to charge $2.1 million for its gene therapy — and the backlash to news organizations pointing that out. Then, Bloomberg reporter Kristen Brown joins us to discuss how companies are struggling to make money in the world of consumer genetic testing. Finally, we delve into a scandal at MIT that finds one professor accusing another of academic malfeasance.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

No hay comentarios: